CureVac NV Market Cap ($885.32 Million)
Market Cap & Net Worth: CureVac NV (5CV)
CureVac NV market cap. CureVac NV (F:5CV) has a market capitalization of $885.32 Million (€757.26 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #9102 globally and #1166 in its home market, demonstrating a 10.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CureVac NV's stock price €3.91 by its total outstanding shares 225172749 (225.17 Million). Also see CureVac NV operating cash flow efficiency for how efficiently the company converts equity into cash flow.
CureVac NV Market Cap History (2020–2026)
CureVac NV market cap history from 2020 to 2026. Data shows change from $19.30 Billion to $1.03 Billion (-35.19% CAGR). Check current stock price of CureVac NV for real-time trading data and today's change.
CureVac NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CureVac NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CureVac NV equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.46x
CureVac NV's market cap is 1.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.80x
CureVac NV's market cap is 4.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $19.30 Billion | $48.90 Million | -$129.80 Million | 394.71x | N/A |
| 2021 | $7.95 Billion | $102.99 Million | -$411.72 Million | 77.17x | N/A |
| 2022 | $1.48 Billion | $67.42 Million | -$249.03 Million | 22.00x | N/A |
| 2023 | $1.01 Billion | $53.76 Million | -$260.17 Million | 18.80x | N/A |
| 2024 | $779.22 Million | $535.18 Million | $162.19 Million | 1.46x | 4.80x |
Competitor Companies of 5CV by Market Capitalization
Companies near CureVac NV in the global market cap rankings as of November 4, 2026. Also see CureVac NV assets under control for a full breakdown of the balance sheet.
Key companies related to CureVac NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of CureVac NV (2020–2026)
Market capitalization of CureVac NV from 2020 to today. Between 2020 and today, CureVac NV's market cap moved from $19.30 Billion to $ 1.03 Billion, with a yearly change of -35.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.03 Billion | +8.32% |
| 2025 | €949.28 Million | +21.82% |
| 2024 | €779.22 Million | -22.92% |
| 2023 | €1.01 Billion | -31.85% |
| 2022 | €1.48 Billion | -81.33% |
| 2021 | €7.95 Billion | -58.82% |
| 2020 | €19.30 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of CureVac NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $885.32 Million USD |
| MoneyControl | $885.32 Million USD |
| MarketWatch | $885.32 Million USD |
| marketcap.company | $885.32 Million USD |
| Reuters | $885.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more